A novel approach for residual malaria transmission, combining targeted treatment of potential malaria carriers with a strong community involvement (both households of malaria patients; and, other organizations/structures in the communities), i.e. reactive household-based self-administered treatment (RHOST), will be tested through a community-based, cluster-randomized trial. Malaria patients (or their parents for children) diagnosed in health facilities will be given sufficient dihydroartemisinin-piperaquine to treat all household members. A formative research approach will be used to adapt RHOST to the local context in an initial phase. The primary outcome will be malaria infection prevalence. The intervention’s impact on the community, the local health system and its incremental cost and cost-effectiveness will also be determined.
|Effective start/end date||1/10/15 → 31/07/19|
- Medical Research Council, United Kingdom: €451,887.56